Nul operates a subscription-based, fully remote programme that integrates clinical care, naltrexone prescriptions, virtual consultations, and structured digital guidance grounded in The Sinclair Method to help users cut back on alcohol without forcing immediate abstinence. Founded by Matus Maar, the company positions itself as a modern, discreet alternative to traditional alcohol-use-disorder treatments, filling a gap that has seen little innovation compared with other telehealth categories such as weight loss or mental health. In a UK test phase launched in summer 2025, Nul attracted more than 120 paying customers and quickly achieved an annualised revenue run rate exceeding £300,000, driven largely by organic referrals. The platform’s early traction underscores demand for evidence-based, tech-enabled alcohol reduction solutions. Looking ahead, Nul plans a full commercial rollout across the UK, expansion of its clinical and product teams, and aggressive customer-acquisition efforts. The company is also laying groundwork for international expansion, with the U.S. identified as a priority market. A forthcoming Republic Europe crowdfunding campaign will allow retail investors to join its next growth stage alongside institutional backers.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2026